BDBM603925 Ethyl 2-ethyl-2-{[6-({(1S,2S)-2-[(2-fluoroethoxy)methyl]cyclopropyl}methoxy)-5-(3-methoxyazetidin-1-yl)pyridine-2-carbonyl]amino}butanoate and ethyl 2-ethyl-2-{[6-({(1R,2R)-2-[(2-fluoroethoxy)methyl]cyclopropyl}methoxy)-5-(3-methoxyazetidin-1-yl)pyridine-2-carbonyl]amino}butanoate::US11655243, Example 2

SMILES CCOC(=O)C(CC)(CC)NC(=O)c1ccc(N2CC(C2)OC)c(OC[C@H]2C[C@@H]2COCCF)n1

InChI Key InChIKey=YPEOHYPTYUXHAK-UHFFFAOYSA-N

Data  1 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 603925   

TargetCannabinoid receptor 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM603925(US11655243, Example 2 | Ethyl 2-ethyl-2-{[6-({(1S,...)
Affinity DataKi:  3.70nMAssay Description:The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
Go to US Patent